Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA (R) (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST).

Next Previous
X
Search
Trial Profile

Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA (R) (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efalizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms CLEAREST™-TRAIL
  • Sponsors Merck Serono

    • Most Recent Events

    • 01 Apr 2022 According to the EudraCT record, this trial has been completed in France (date of the global end of the trial 2009-07-31).
    • 26 Sep 2011 According to the EudraCT record, this trial is recruiting in France, but has prematurely ended in Germany, Austria, Netherlands and Portugal.
    • 23 Sep 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top